Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Group ACYW135 Meningococcal Conjugate Vaccine in Children Aged 2-6 Years
NCT07505888Phase 3Active, not recruiting
- Sponsor
- Sinovac Biotech Ltd.
- Start
- Mar 2026
- Primary completion
- Nov 2026
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of Sinovac ACYW135 Meningococcal Conjugate Vaccine in meningococcal meningitis (2 arms), sponsored by Sinovac Biotech Ltd. Primary endpoints: Seroconversion rates of Nm antibodies for serogroups A, C, Y, W135 at Day 30 and Geometric Mean Titers of Nm antibodies for serogroups A, C, Y, W135 at Day 30. Started Mar 2026; status: active, not recruiting.
02
Drugs
Sinovac ACYW135 Meningococcal Conjugate Vaccine
03
Conditions
meningococcal meningitis
Beyond the preview
Go deeper on NCT07505888.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07505888.